Berkeley Lights Announces Opto™ Assure For Early Manufacturability Assessment of Antibody Therapeutics
With Opto Assure, customers can rapidly select clonal cell lines with favorable manufacturability profiles, leading to decreased scale-up costs and better downstream products.
- With Opto Assure, customers can rapidly select clonal cell lines with favorable manufacturability profiles, leading to decreased scale-up costs and better downstream products.
- Berkeley Lights enhances its technology leadership position in cell line development by going beyond titer assessment in the clone selection process.
- Opto Assure helps minimize risk of costly late stage failures by identifying clones early on that secrete product with high yield and desired quality.
- The Berkeley Lights Platform and the Berkeley Lights Beacon and Lightning systems and Culture Station instrument are FOR RESEARCH USE ONLY.